SLE with Thrombotic Antiphospholipid Syndrome After a First Thrombotic Event

Patients with systemic lupus erythematosus (SLE) who develop thrombotic antiphospholipid syndrome (APS) represent a high-risk subgroup requiring a specific long-term management strategy, particularly following a first arterial or unprovoked venous thrombotic event.

Clinical Scenario

Systemic lupus erythematosus with thrombotic antiphospholipid syndrome, occurring in the context of a first arterial or unprovoked venous thrombotic event. This presentation requires targeted secondary prevention to reduce the risk of recurrent thrombosis.

Treatment Approach

Long-term anticoagulation with a vitamin K antagonist forms the cornerstone of management in this setting. In addition, a specific antimalarial agent is particularly recommended for its established antithrombotic properties in SLE patients with antiphospholipid antibodies.

Full regimen details, sequencing, and monitoring targets available via the structured protocol →

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/ard-2023-224762

SLE associated with thrombotic antiphospholipid syndrome (APS) should be managed with long-term vitamin K antagonists after the first arterial or unprovoked venous thrombotic event (1b/B).

Apart from its other beneficial effects, HCQ has also potential antithrombotic effects and may reduce aPL levels, and is particularly recommended in patients with SLE-aPL or SLE/APS.

View source ↗